Archive for the 'Provigil @ Google News' Category

« Previous Entries
Next Entries »

Ranbaxy falls 7% to nine-month low on USFDA settlement costs – Economic Times


IBNLive.com
Ranbaxy falls 7% to nine-month low on USFDA settlement costs
Economic Times
"We think Ranbaxy has lost first to file (FTF) status on products slated for launch in the near term: Actos (August 2012), Clarinex 5 mg (July 2012 launch) and Provigil (April 2012) or Diovan (March 2012)," she wrote in a note. Selling generic Actos in …
Don't get excited about pharma cos with USFDA issues: IIFLMoneycontrol.com
Nexium, Actos, or Diovan? Analysts try to ID Ranbaxy's 3 sacrificesFiercePharma

all 8 news articles »

January 27th, 2012 | Posted in Provigil @ Google News, Uncategorized | No Comments

Share market, analysts give Ranbaxy a thumbs down – Business Standard


Business Today
Share market, analysts give Ranbaxy a thumbs down
Business Standard
Cephalon's sleep disorder drug, Provigil, and Novartis' blood pressure drug, Diovan, were also among the speculative list of exclusive marketing opportunities at risk. “We expect it to be generic Provigil, Diovan and Valcyte, contributing sales of $186 …
Ranbaxy falls 7% to nine-month low on USFDA settlement costsEconomic Times
Ranbaxy Falls Most Since March on Settlement Costs: Mumbai MoverBusinessWeek
Ranbaxy scrip tanks 7% on 'harsh settlement' in USTimes of India
Calcutta Telegraph -Hindu Business Line
all 154 news articles »

January 27th, 2012 | Posted in Provigil @ Google News, Uncategorized | No Comments

Nexium, Actos, or Diovan? Analysts try to ID Ranbaxy’s 3 sacrifices – FiercePharma

Nexium, Actos, or Diovan? Analysts try to ID Ranbaxy's 3 sacrifices
FiercePharma
Nomura Holdings identified the Cephalon ($CEPH) wakefulness drug Provigil, with $1.1 billion in US sales in 2010; the Takeda Pharmaceuticals ($TKPHF) diabetes pill Actos, with $3.35 billion; and the Novartis ($NVS) blood-pressure remedy Diovan, …

January 27th, 2012 | Posted in Provigil @ Google News, Uncategorized | No Comments

Ranbaxy: The long and winding road to salvation – Hindu Business Line


Hindu Business Line
Ranbaxy: The long and winding road to salvation
Hindu Business Line
… 2010 (off patent in September 2012), the sleep disorder drug Provigil, which has a $1.1-billion sales in 2010 and AstraZeneca's heart-burn treatment drug Nexium that had an annual sales of $5.2 billion in 2010 (expected to be launched in May 2014).
Sell Ranbaxy Labs; target of Rs 355: PINC ResearchMoneycontrol.com

all 139 news articles »

January 27th, 2012 | Posted in Provigil @ Google News, Uncategorized | No Comments

« Previous Entries
Next Entries »